esomeprazole 20mg gastro-resistant capsules
actavis uk ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg
flumazenil 500micrograms/5ml solution for injection ampoules
actavis uk ltd - flumazenil - solution for injection - 100microgram/1ml
bicalutamide 50mg tablets
actavis uk ltd - bicalutamide - oral tablet - 50mg
ropinirole 5mg tablets
actavis uk ltd - ropinirole hydrochloride - oral tablet - 5mg
chlordiazepoxide 5mg capsules
actavis uk ltd - chlordiazepoxide hydrochloride - oral capsule - 5mg
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited. there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.
co-codamol 8mg/500mg tablets
actavis uk ltd - paracetamol; codeine phosphate - oral tablet - 500mg ; 8mg
co-dydramol 10mg/500mg tablets
actavis uk ltd - paracetamol; dihydrocodeine tartrate - oral tablet - 500mg ; 10mg
paracetamol 500mg tablets
actavis uk ltd - paracetamol - oral tablet - 500mg
clopidogrel 75mg tablets
actavis uk ltd - clopidogrel - tablet - 75mg